HCV NS-3 serine protease inhibitors

US7608590B2 · kind B2 · utility

Assignee

• MEDIVIR AB · SE

Inventors

• Asa Annica Kristina Rosenquist · Huddinge, SE
• Fredrik Thorstensson · Linköping, SE
• Per-Ola Mikael Johansson · Linköping, SE
• Ingemar Kvarnstrom · Linköping, SE
• Susana Ayesa · Huddinge, SE
• Bjorn Classon · Stockholm, SE
• Laszlo Rakos · Malung, SE
• Bertil Samuelsson · Huddinge, SE

Key dates

• Filing date: Jan 28, 2005
• Grant date: Oct 27, 2009
• Expiry date: Jan 28, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formulawhere the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.